Back to results
US 10,351,910 B2Granted
Gene and protein expression properties of adherent stromal cells cultured in 3D
AssigneePluristem Ltd.
InventorsRachel Ofir, Eytan Abraham
Life of this patent
Estimating the term…
Abstract
Adherent stromal cells cultured under three dimensional conditions are provided, characterized, and distinguished from adherent stromal cells cultured under two dimensional conditions.
Claims15
A method of treating an autoimmune disease in a subject in need thereof, comprising:
- a. determining whether an ASC was produced by 3D culture, wherein said 3D culture comprises polyester 3D carriers, said method comprising:
- i. measuring in a sample of ASC the expression of 1 or more biomarkers comprising VEGFA, LIF, COL7A1, IL6, MMP10, MMP9, MMP11, FN1, COL15A1, TNC, or IFNA1, wherein said one or more biomarkers comprise VEGFA, and said measuring is performed using gene array or PCR, and
- ii. comparing the measured levels to levels of the same biomarker measured in a sample of ASC produced by 2D culturing (“2D control”);
- wherein an increase of at least 2-fold of any 1 or more of VEGFA, LIF, COL7A1, IL6, MMP10, MMP9, MMP11, FN1, COL15A1, TNC, or IFNA1 relative to the 2D control indicates the cell is an ASC produced by 3D culturing comprising polyester 3D carriers;
- and
- b. administering said ASC to said subject, thereby treating an autoimmune disease.
3 more elements
A method of treating an autoimmune disease in a subject in need thereof, comprising:
- a. determining whether an adherent stromal cell was produced by three dimensional culture, wherein said three dimensional culture comprises polyester three dimensional carriers, said method comprising:
- i. measuring in a culture medium produced from a sample of adherent stromal cells the expression of VEGFA detecting or measuring, wherein said measuring is performed using antibody array or ELISA, and
- ii. comparing the measured levels to levels of the same biomarker measured in a sample of culture medium produced from adherent stromal cells grown in two dimensional culturing (“2D medium control”);
- wherein an increase of at least two-fold of VEGFA relative to the 2D medium control indicates the cell is an adherent stromal cell produced by three dimensional culturing comprising polyester three dimensional carriers;
- and
- b. administering said ASC to said subject, thereby treating an autoimmune disease.
3 more elements
Dependencies are inferred from the claim text.